Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
SGLT Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2023
SGLT Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Sodium-Glucose Co-Transporter (SGLT) is a member of the family of glucose transporters found in the human body. These play a significant function in reabsorbing glucose from the part in which they are present, depending upon the type of SGLT present. There are 2 types of SGLT present depending upon the location: SGLT-1 and SGLT-2. SGLT-1 is present in the brush border epithelium lined by the enterocytes, where it is responsible for glucose reabsorption from the intestine. SGLT-2 is present in the renal cortex, which absorbs glucose from the glomerular filtrate in the early and middle segments of the Proximal Convoluted Tubule (PCT). These cotransporters play a significant role by regulating the glucose level in the body, hence, are a good target for drugs that aim to lower the blood glucose level in the body by indirect action, i.e., prevent absorption and increase excretion of glucose. Research is being conducted globally to discover new and novel molecules to be used as Anti-Diabetic agents. The development and launch of new products will thus increase the revenue of the market in the forecasted years. For instance, according to the International Diabetes Federation, in 2021, approximately 537 million people in the age bracket of 20-79 years globally are suffering from diabetes and counting. So, there is a huge market for the players to launch their products in the market in the near future.
A number of SGLT-1 inhibitors are on the market, while many are in ongoing clinical trials. 12 companies have various SGLT-1 inhibitors in their pipelines, with 8 products in various stages of clinical trials, 1 product in Phase 4, 1 product in Phase 3, 4 products in Phase 2, and 2 products in Phase 1 of the clinical trials. Moreover, 42 companies have various SGLT-2 Inhibitors in their pipelines, with 43 products in various stages of clinical trials, 17 products in Phase 4, 5 products in Phase 3, 4 products in Phase 2, and 12 products in Phase 1 of the clinical trials.
Key Developments
Approved SGLT-1 Inhibitor drugs
SGLT-1 Inhibitor drugs in Pipeline
SGLT-2 Inhibitor drugs in Pipeline
Clinical Activity and Developments of SGLT Inhibitors
As of June 2023, companies have approximately 8 products for 14 diseases. For these diseases, 7 trials are being conducted by players globally. For instance,
|
SGLT-1 Inhibitor Molecule name |
Number of studies |
|
Inpefa (sotagliflozin) |
53 |
|
licogliflozin (LIK066) |
12 |
|
mizagliflozin (VGX-3235) |
8 |
|
Canalia (teneligliptin/canagliflozin) |
3 |
|
SY-009 |
3 |
As of June 2023, 42 companies have approximately 43 products for 45 diseases. For these diseases, 393 trials are being conducted by players globally. For instance,
|
SGLT-2 Inhibitor Molecule name |
Number of studies |
|
Farxiga (dapagliflozin) |
785 |
|
Jardiance (empagliflozin) |
462 |
|
Invokana (canagliflozin) |
183 |
|
Inpefa (sotagliflozin) |
105 |
|
Suglat (ipragliflozin) |
88 |
Drugs like Jardiance and Farxiga have been approved by the FDA and other regulatory authorities for various indications and diseases. These are also in the clinical trials for other disorders and show encouraging results. SGLT Inhibitors are in clinical trials for many indications like Type 1 and Type 2 Diabetes Mellitus, Endocrine system diseases, Metabolic disorders, Hypertension, Atherosclerosis, and others. SGLT Inhibitors are also being tried to control body weight in obese patients, Hyperglycaemia, Hyperinsulinism, insulin resistance, and nutrition disorders. There is an excellent opportunity for the players of SGLT Inhibitors in the market with the rising prevalence of the diseases globally.
The prevalence of Diabetes Mellitus has been rising globally for decades, and companies are trying to launch new products to meet the unmet needs of the people. AstraZeneca’s Farxiga and Eli Lilly’s Jardiance have been in the market for various indications. Farxiga had net sales of $1,177 million in the 4th quarter of 2022 in the US market, which was 11% more than compared to the 4th quarter of 2021, while the total sales in the financial year 2022 were USD 4,381 million with an increase of 46% as compared to the last years’ sales. Jardiance had net sales of $612.3 million globally in the 4th quarter of 2022, which was 42% more as compared to the 4th quarter of 2021, while it had net sales of $2,066 million in the financial year 2022, which was 39% higher than the sales of Jardiance in the financial year 2021.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Farxiga (dapagliflozin), Jardiance (empagliflozin) and Invokana (canagliflozin) are some of the SGLT-2 Inhibitors have been approved by the FDA while Inpefa (sotagliflozin) is the SGLT-1 Inhibitor approved by the FDA.
These are being used in various indications like Type 1 and Type 2 Diabetes Mellitus, Hypertension, Atherosclerosis, Endocrine system diseases, Metabolic diseases and others
Lexicon Pharmaceuticals, Novartis, Vogenx, Mitsubishi Tanabe and Daiichi Sankyo are some of the major market players for SGLT Inhibitors.
Rising incidence of diseases, improvement in technologies, development of new treatment lines in the market, and changing lifestyles leading to Diabetes Mellitus, Glucose intolerance, and metabolic disorders are the key opportunities for SGLT Inhibitors in the market.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.